Ionis Pharmaceuticals Stock News

Wall Street analysts expect that Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) will post $233.97 million in sales for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Ionis Pharmaceuticals earnings. The highest sales estimate is $239.50 million and the lowest is $230.10 million. Ionis Pharmaceuticals reported sales of $290.00 million in []

CARLSBAD, Calif., Nov. 9, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in virtual fireside chats at the following virtual investor

Ionis (IONS) incurs wider-than-expected Q3 loss. The company maintains its top-and bottom-line guidance for 2021

Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q3 2021 Results - Earnings Call Transcript

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -9.43% and -16.81%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st

An experimental treatment for amyotrophic lateral sclerosis missed the mark in a phase 3 trial.

CARLSBAD, Calif., Oct. 20, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 3 rd at 11:30 a.m.

The stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, plunged 14% in yesterday's trade to its five year low levels of $3

CARLSBAD, Calif., Oct. 17, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) partner Biogen today announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of to

These stocks could be attractive at discounted prices.

CARLSBAD, Calif., Sept. 3, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today it will present 14 posters and two symposiums highligh

CARLSBAD, Calif., Sept. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a company overview at the following virtual investor conference

Ionis: Should One Failure Cause So Much Distress?

Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q2 2021 Results - Earnings Call Transcript

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -1.79% and -9.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?